The start-up PharmAI was founded in 2019 as a spin-off from the TU Dresden. The company’s core software DiscoveryEngine is based on the analysis of 3D protein structure data. It uses information on the composition of proteins in the human body, viruses, or diseases and extracts knowledge on how these proteins interact with drugs and other small molecules. This is a kind of jigsaw puzzle driven by the unique way how small molecules interact with binding pockets – small cavities on the protein surface. The technology, which is based on artificial intelligence, is used by its customers to find new molecules for the treatment of diseases or to detect undesired side effects in a very short time. PharmAI currently has eight team members.